Open Access Open Access  Restricted Access Subscription Access

UV-Spectroscopic Methods Development and Validation for Estimation of Desidustat

Rutvik Pandya, Heta Kachhiya, Mubassira N. Desai, Dipexa Patel, Bindiya L. Paradeva, Jinal Tandel

Abstract


Zero order, first order derivative and Difference spectrophotometric methods were developed for routine estimation of Desidustat and validated as per ICH guideline. Linearity obtained for zero order and first order derivative methods from 2-7 g/ml with R2 0.9965 and 0.9961, respectively and for difference spectrophotometric method 4-12 g/ml. with R2 0.9978. Standard spiking method for accuracy study was performed and % recovery was found 99.01 to 99.51 % for zero order, 99.49 to 101 % for first order derivative and 99.6 to 101.85 % for difference spectrophotometric method. LOD and LOQ values were 0.33 g/ml and 1.0 g/ml for Desidustat by zero order derivative method. LOD and LOQ values were 0.80 g/ml and 2.44   g/ml for Desidustat by first order derivative method. LOD and LOQ values were 0.75 g/ml and 2.28 g/ml for Desidustat by difference spectrophotometric method. All developed methods are simple, accurate, precise, rapid, cost effective and less time-consuming, repeatable for the analysis of Desidustat for routine analysis.

 


Full Text:

PDF

References


Drug bank “Desidustat”, https://go.drugbank.com/drugs/DB16135 (Accessed on: February 21, 2021)

Pubmed “Desidustat”, https://pubmed.ncbi.nlm.nih.gov/35834123/ (Accessed on: April 22, 2022).

H. Patel, N. Modi and J. Chaudhari (2022). Nonclinical pharmacokinetic evaluation of Desidustat: a novel prolyl hydroxylase inhibitor for the treatment of anemia, Eur. J Drug Metabol. Pharmacokinet. 47, 725 – 740.

D. Parmar, K. Kansagra, J. Patel, S. Joshi, N. Sharma, A. Shelat, N. Patel, V. Nakrani, F. Shaikh and H. Patel (2019). Trial investigators. outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study, Am. J. Nephrol. 49, 470-478.

Q. Zheng, H. Yang, L. Sun, R. Wei, X. Fu, Y. Wang, Y. Huang, N. Liu and W. Liu (2020). Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis, Pharmacol. Res. 159. doi: 10.1016/j.phrs.2020.105020

S. Hasegawa, T. Tanaka and M. Nangaku (2018). Hypoxia‐inducible factor stabilizers for the anemia of chronic kidney disease, Curr. Opin. Nephrol. Hypertens. 27, 331-338.

M. Sugahara, T. Tanaka and M. Nangaku (2022). Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors, Pharmacol. Ther. 239,doi: 10.1016/j.pharmthera.2022.108272

R. Pandya, H. Kachhiya, D. Solanki, J. Tandel, U. Chhalotiya and D. Shah (2023). Sensitive, precise, accurate, and economic planar chromatographic method developed and validated for quantification of Desidustat as per guideline, Sep Sci plus. 6. doi:10.1002/sscp.202300069

J. Prajapati (2023). Stability Indicating RP-HPLC method development and validation for the analysis of desidustat in tablet dosage form, IJNRD 8, 55-73.

R. Patel and P. Yadav (2023). Stability indicating RP-HPLC method development and validation for the estimation of desidustat in tablet dosage form, World J. Pharm. Pharmaceut. Sci. 4(8), 1145-1152.


Refbacks

  • There are currently no refbacks.